Kornimate/medical-research-clean huggingface dataset:
get in shape in the team research: porukalla kuntoon tutkimus

Conditions: Aging; Muscle Strength

Summary: it is well accepted that physical activity in the form of resistance training produces a wide variety of neuromuscular-skeletal and health benefits. it is recommended in finland that older individuals (over 65yr) should perform resistance training twice per week. unfortunately, only approx. 5% of older individuals fulfill this recommendation. as finnish society grows ever older, research should focus on the specific needs of this group and how to improve participation in physical activity, which may ultimately lead to modification of physical activity recommendations - resistance training recommendations are currently the same for young and older adults and do not include specific recommendations on the type of resistance training. however, these recommendations appear to have been developed for "best possible" improvements in maximum strength and muscle size. therefore, it is of great importance to identify the number of resistance training sessions per week required to induce improvements in physical fitness, metabolic and bone health status, and importantly the reasons for adherence to/drop-out of resistance training interventions (e.g. motivation to train) in a multi-discipline study. this knowledge would benefit policy makers to update current recommendations for resistance training and to devise strategies to advise realistic targets for resistance training in the older, particularly the less-educated, age group (e.g. teli-strategy for 2020). the present study will include a 12-month resistance training intervention with a 12-month follow-up period. interviews and questionnaires will assess psychological/sociological data and will be collected from both drop-out subjects and those that complete the intervention. neuromuscular performance and functional capacity will be tested using conventional methods, along with body composition, bone density, and blood tests for metabolic markers of health. diet and other physical activity will be controlled throughout the intervention period. measurements are to be performed every 3 months. it is expected that 5 international peer-reviewed articles will be published in 2016-2017. the data will be presented at international and national conferences in 2015-2017. finally, results of the entire research will be published in national peer-reviewed journals (e.g. the age institute's "raportteja"). all subjects will be invited to attend an information meeting where group results will be presented and explained.


Eligibility criteria:
inclusion criteria: * bmi\<37 * does not smoke * able to perform all tests and exercises * free from episodes during physical activity exclusion criteria: * bmi\>37 * use of waling aids * previous testosterone-altering treatment, e.g. in cancer treatment or hypogonadism * serious cardiovascular disease that may lead to complications during exercise * use of pharmaceuticals that affect neuromuscular or endocrine systems * regular endurance training\>3hr per week * resistance training experience

Keywords: aging sarcopenia resistance training strength muscle mass
safety & efficacy of a single dose of sumatriptan powder delivered intranasally with the bi-directional device in adults with acute migraine

Conditions: Migraine Headache

Summary: the study is being conducted to determine if optinose sumatriptan delivered nasally (through the nose) using the optinose sumatriptan device can reduce the pain and symptoms associated with migraine headaches.

the primary objective for this study is to compare headache relief (defined as a reduction from moderate \[grade 2\] or severe \[grade 3\] pain to none \[grade 0\] or mild \[grade 1\] pain) at 120 minutes following a dose of 20 mg of optinose sumatriptan with placebo in the acute treatment of a single migraine attack.

Eligibility criteria:
inclusion criteria: * men or women, between the ages of 18 to 65 years * diagnosis of migraine, with or without aura * experiences between 1 and 8 migraine attacks per month for the past 12 months exclusion criteria: * inability to distinguish other headaches from migraine * experiences headache of any kind at a frequency greater than or equal to 15 days per month * history of resistance to sumatriptan, or non-response to 2 or more other triptans, defined as subjects who have not responded to an adequate dose and duration of treatment * current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening * chronic opioid therapy (\>3 consecutive days in the 30 days prior to screening)

Keywords: migraine headache sumatriptan
are two antidepressants a good initial treatment for depression?

Conditions: Major Depression; Dysthymia; Depression NOS

Summary: relatively drug naive patients will receive two antidepressant medications as initial treatment.

while antidepressant medications are often effective in relieving depressive symptoms, at least 60% of patients do not remit with the first agent tried. this pilot study will assess whether giving two standard medications simultaneously (i.e., escitalopram and bupropion) is both tolerated and improves response while decreasing drop outs. this is a replication of a previous study.

Eligibility criteria:
inclusion criteria: * currently depressed (dsm-iv major depression, dysthymia or depression nos) * hamd-d (21-item) \> 9 exclusion criteria: * prior ineffective adequate trial on either study medication ($ 4 weeks on either escitalopram \>20 mg/d or bupropion \>300 mg/d; \>4 weeks on citalopram \>40 mg/d) * history suggesting increased risk for seizures (e.g., prior seizure as an adult, diagnosed seizure disorder, taking medication known to increase seizure risk, history of significant head trauma, history of bulimia or anorexia) * history of intolerance to either study medication unless patient and m.d. agree side effect is probably manageable * alcohol and/or drug abuse/dependence during past year * major medical problems that are not well controlled (e.g., untreated hypertension or diabetes) * bipolar i, bipolar ii * history of psychosis, or current psychosis * currently taking antidepressants or mood stabilizers, which is judged unwise to discontinue (occasional sleep medication or benzodiazepine for anxiety is allowed) * not currently depressed (whether considered due to current treatment or not) * active suicidal risk (history of suicide attempts will be evaluated on a case by case basis) * pregnant or breast-feeding * premenopausal women not using known effective birth control

Keywords: major depression dysthymia depression nos escitalopram bupropion dual therapy combination therapy
stereotactic pelvic adjuvant radiation therapy in cancers of the uterus ii

Conditions: Endometrial Cancer

Summary: adjuvant radiotherapy (rt) plays an important role in reducing the risks of local recurrence after surgery in uterine cancers. standard adjuvant pelvic radiation treatment targets the pelvic lymph nodes, the post-operative bed, and the upper vagina and is typically treated with intensity modulated radiation therapy (imrt) which has been shown to improve patient reported gastrointestinal (gi) and genitourinary (gu) toxicities. although pelvic radiation has been shown to be effective at decreasing locoregional recurrences, patient quality of life and experience can be significantly impacted as pelvic rt comprises of daily radiation for 25 daily treatments, which can be a substantial burden on patients with this disease. hypofractionated radiotherapy to a dose of 30 gy in 5 fractions (6 gy given every other day) for adjuvant radiation treatment in uterine cancer is hypothesized to result in similar rates of acute gastrointestinal toxicities as conventional fractionated radiation.


Eligibility criteria:
inclusion criteria: 1. patient with histologically confirmed endometrial adenocarcinoma, serous or clear cell carcinoma. 2. patient is a candidate for adjuvant pelvic radiation for uterine cancer (+/- vault brachytherapy), meeting one of the following conditions: high grade histology (including serous and clear cell) or outer-half myometrial invasion and international federation of gynecology and obstetrics (figo) grade 1-2 or figo stage ii - iii. 3. patients who are to receive adjuvant systemic therapy sequentially in addition to pelvic radiotherapy will be eligible. 4. age ≥18 years. 5. patient is willing and able to give informed consent to participate in this clinical trial. exclusion criteria: 1. patient has had prior pelvic radiotherapy. 2. patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease. 3. patient planned for concurrent chemoradiation therapy.

Keywords: endometrial cancer uterine cancer
a phase ii/iii tolerance and efficacy study of rsd1235 in patients with atrial flutter

Conditions: Atrial Flutter

Summary: this study will attempt to demonstrate the effectiveness of rsd1235 in the conversion of atrial flutter (afl) to sinus rhythm.

there are approximately 2 million reported prevalent cases of atrial fibrillation and atrial flutter (afl) in the united states (heart disease \& stroke statistics - 2003 update, aha). these arrhythmias may be occasional or sustained. af/afl is usually associated with age, and general physical condition, rather than with a specific cardiac event, as is often the case with ventricular arrhythmia. while not directly fatal, these arrhythmias cause discomfort and can lead to stroke or congestive heart failure. this phase ii/iii trial is cardiome's first study with rsd1235 for the treatment of atrial flutter. the study seeks to demonstrate rsd1235's abilities to convert afl to sinus rhythm. the patient population will have atrial flutter of duration greater than 3 hours and less than or equal to 45 days. this is a double-blind, placebo-controlled, randomized study in patients with afl; stratification will be based on duration of afl. treatment will be considered successful if there is a treatment-induced conversion of atrial arrhythmia to sinus rhythm for a minimum of 1-minute by hour 1.5 (time 0 = start of first infusion). all patients will be evaluated for safety.

Eligibility criteria:
inclusion criteria: * 18 years of age or older. * have an atrial arrhythmia with dysrhythmic symptoms that has been sustained for greater than 3 hours and up to 45 days. * have adequate anticoagulant therapy. exclusion criteria: * have a qrs \> 0.14 s unless patient has pacemaker or uncorrected qt \> 0.440 seconds as measured on a 12-lead ecg. * be concurrently participating in another drug study or have received an investigational drug within 30 days prior to enrollment, or have previously received rsd1235. * have serious diseases/illnesses that could interfere with the conduct or validity of the study or compromise patient safety. * have received iv class i or class iii antiarrhythmic drugs or iv amiodarone within 24 hours prior to dosing.

Keywords: atrial flutter rsd1235
a study of jnj-67484703 in participants with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate safety and tolerability of jnj-67484703 administrations in participants with active rheumatoid arthritis (ra).

jnj-67484703 is a humanized immunoglobulin g1 kappa (huigg1κ) antibody that is being developed as a treatment for systemic autoimmune disorders. the primary hypothesis of this study is that treatment with jnj-67484703 as compared to placebo will result in a similar tolerability and safety profile, as a measure of participants with abnormalities in vital signs, physical examinations, and laboratory safety tests. this study will be conducted in 3 phases: screening phase (up to 6 weeks), treatment phase (up to 10 weeks), and follow-up phase (up to 14 weeks). the duration of study participation will be approximately 30 weeks. safety assessment like electrocardiogram (ecg), adverse events will be performed during the study. efficacy assessment like joint assessments, pain assessments, ra joint pain severity assessment, patient's and physician's global assessment of disease activity, health assessment questionnaires, duration of morning stiffness, functional assessment of chronic illness therapy-fatigue will be performed during the study.

Eligibility criteria:
inclusion criteria: * demonstrated an inadequate response to, or loss of response or intolerance to: at least 1 conventional synthetic disease-modifying antirheumatic drug (csdmard) and/or up to 2 biologic dmard (bdmard)/targeted synthetic dmard (tsdmard) * have c-reactive protein (crp) greater than or equal to (\>=) 0.3 milligrams per deciliter (mg/dl) at screening * medically stable on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ecg) performed at screening * have a diagnosis of rheumatoid arthritis (ra) (american college of rheumatology \[acr\]/ european league against rheumatism \[eular\] criteria 2010) * body weight within the range of 50.0 kilograms (kg) to 120.0 kg, inclusive, and have a body mass index (bmi) of 19.0 kilograms per meter square (kg/m\^2) to 32.0 kg/m\^2, inclusive * all women must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hcg\]) at screening exclusion criteria: * known allergies, hypersensitivity, or intolerance to any biologic medication or excipients of jnj-67484703 * has a diagnosed or reported history or current signs or symptoms indicating severe, progressive, or uncontrolled hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * have other known inflammatory diseases that might confound the evaluations of benefit from jnj-67484703 therapy * have a history of any clinically significant adverse reaction to murine or chimeric proteins, including, but not limited to, allergic reactions * have a history of or currently have felty's syndrome
observational study on mortality and outcome of patients hospitalized for subarachnoid hemorrhage of aneurysmal origin in martinique between 2013 and 2021

Conditions: Subarachnoid Hemorrhage of Aneurysmal Cause

Summary: the aim of our study is to analyze mortality and sequelae of subarachnoid hemorrhage of aneurysmal origin in hospitalized patients in martinique. predictive factors of poor prognosis will also be analyzed.

subarachnoid hemorrhage is an uncommon pathology in the general population, with a worldwide incidence of 9 per 100,000 people/year, but with a non-negligible risk of sequelae in terms of impairments, activity limitations and participation restrictions of around 30%. mortality remains high at 40%, despite increasingly specialized care. in addition, there are a number of objective, rapid assessment scores for autonomy and impairments, notably the modified rankin score, which is not specific to subarachnoid hemorrhage, but which enables the study of patients' perceived quality of life. certain factors predictive of bad patient outcome are known in the literature, but have been little studied in the population of martinique.

Eligibility criteria:
inclusion criteria: * adult (≥18 years) patients, * admitted to university hospital of martinique with subarachnoid hemorrhage of aneurysmal origin between 01/01/2013 and 31/12/2021, * informed patient/next-of-kin/treating physician consent for research participation. exclusion criteria: * other causes of subarachnoid hemorrhage of non-aneurysmal origin (traumatic, arteriovenous malformation, cerebral tumor, cerebral thrombophlebitis).

Keywords: sah (subarachnoid hemorrhage) ruptured intracranial aneurysm modified rankin score mortality patient autonomy patient dependence
natto supplementation to prevent loss of bone mass in women immediately after menopause

Conditions: Perimenopausal Bone Loss

Summary: study objective: to determine whether natto supplementation in women immediately after menopause might prevent severe bone loss study population: women 50 - 60 years, 1-5 years after menopause study design: double-blind, placebo-controlled, randomized controlled trial. a "phase ii" clinical trial. instruments used to measure therapeutic response: lunar prodigy dexa bone densitometer study treatment group: daily supplementation with vitamin k2, "natto" study control group: identically-looking placebo medication duration of treatment: 12 months duration of subject participation in study: 12 months assessment of therapeutic response: given an expected reduction of bone mass density of - 1.1% annually in the placebo group, the minimum clinically significant difference between the groups is 0.3 percentage points. the trial is therefore powered to detect a reduction in annual bone mass loss of 0.3 percentage points in the treatment group. numbers of evaluable subjects required: 304 maximum # subjects 334


Eligibility criteria:
inclusion criteria: * women living in the city of tromsø, not using hormone replacement therapy, 1-5 years after menopause. exclusion criteria: * history of hip fracture * bone disease affecting bone mineral density * use of vitamin k antagonists * significant co-morbidity that makes it difficult to obtain bmd measurements * use of hormone replacement therapy or other therapy that influence bone remodeling

Keywords: women bone density menopause dietary supplements vitamin k2
baseline investigation of chronic hepatitis b viruses infections: who is eligible for treated criteria

Conditions: Hepatitis B

Summary: through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic hbv infection-related liver disease population.

hepatitis b virus (hbv) infection is a major public health problem worldwide. china has the world's largest burden of hbv infection and will be a major contributor towards the global elimination of hepatitis b disease by 2030. while, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic hbv infections is still unknown. in response to the above situation, sampling applied a two-stage stratified cluster sampling design in 16 districts and 331 townships. investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in beijing.

Eligibility criteria:
inclusion criteria: * older than 25 years old; * residents with medical insurance coverage lived in beijing more than 6 months . exclusion criteria: * persons with pacemakers; * pregnant women; * persons with ascites; * the one whose wound was not cured at the right upper abdomen

Keywords: hbv antiviral treatment rate china baseline investigation
a study to understand the utility of the force feedback instruments in robotic procedures using da vinci 5 robot

Conditions: Hernia, Inguinal; Hernia, Ventral; Colorectal; Thoracic; Gynecologic; Partial Nephrectomy

Summary: the goal of this observational study is to understand the utility of force feedback instruments in surgeries that are done using the da vinci 5 robot.


Eligibility criteria:
pre-operative inclusion criteria: 1. age 22 years or older 2. asa ≤ 3 3. the clinical decision has been made to perform multi-port robotic assisted surgery with da vinci 5 with force feedback instruments for the study specified procedure as primary procedure prior to enrollment in the study 4. subject or a legally authorized representative is able to provide written informed consent using the study informed consent form prior to the study 5. subject is willing and able to comply with the study protocol requirements including follow up schedule pre-operative exclusion criteria: * subject receiving an emergent procedure * subject planned to undergo major concomitant surgery for the treatment of a different medical condition than was originally planned * subject with previous ipsilateral surgery (open, endoscopic or robotic) with the same surgical indication * subject with past or ongoing medical conditions (for example: inflammatory bowel disease) which, in the judgment of the investigator, puts them at high risk for surgery and not appropriate for the study * subject is pregnant or suspected to be pregnant or breastfeeding * subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete quality data * subject is currently participating in or has participated in a study of an investigational agent or a significant risk investigational device study within the past 6 months * subject belongs to a vulnerable population. * subject is contraindicated for anesthesia or surgery. * subject has had previous neoadjuvant therapy, previous chemotherapy, immunotherapy, and/or radiation therapy for the treatment of the cancer to be resected within the past 6 months intra-operative exclusion criteria * subject with hemodynamic or respiratory instability, which precludes the investigator from performing the ras. * subject in whom inadequate visualization makes a minimally invasive approach not feasible, as determined from the investigator assessment prior to docking the robot. * subject with adhesions, scarring and disease status in the body which in the opinion of the investigator limits the ability to perform the minimally invasive procedure.